Accessibility Menu
Bionano Genomics logo

Bionano Genomics(NASDAQ) BNGO

Current Price$1.12
Market Cap$12.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-68%
1 Month-3%
Bionano Genomics last closing stock price
MetricPriceDate
Last closeUSD 1.122026-07-22
Bionano Genomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.88%USD 1.192026-07-15
1 month-2.61%USD 1.152026-06-22
3 month-7.44%USD 1.212026-04-23
Year to date-26.8%USD 1.532025-12-31
1 year-68.27%USD 3.532025-07-22
3 year-99.69%USD 358.082023-07-21
5 year-99.97%USD 3,582.002021-07-23
Since inception-99.97%USD 4,193.992018-09-21

Bionano Genomics Financials at a Glance

Market Cap

$12.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$28.74M

Net Income (TTM)

-$31.60M

EPS (TTM)

-$5.08

P/E Ratio

-0.22

Dividend

$0.00

Beta (Volatility)

2.03 (High)

Price

$1.12

Volume

69,445.615

Open

$1.12

Previous Close

$1.12

Daily Range

$1.11 - $1.14

52-Week Range

$1.06 - $5.50

Estimated Earnings Date

Aug 13, 2026

BNGO News

Foolcom-Featured.png

Bionano Genomics Posts Q2 Margin Gain

Motley Fool Markets TeamAug 14, 2025
Illuminated exit sign

Why Bionano Genomics Stock Tanked Today

Eric VolkmanAug 14, 2023
DNA genetic sequencing biotech

Why Shares of Bionano Genomics Are Up Monday

James HalleyApr 24, 2023
scientist looks into microscope while sitting at bench in laboratory

Buy This Magnificent Growth Stock Before It's Too Late

Alex CarchidiMar 16, 2023
scientist pipettes while two others watch in a lab

Is Bionano Genomics Stock a Buy Now?

Alex CarchidiMar 7, 2023
team of scientists work in lab

This Growth Stock Is Down 38% and Wall Street Says It's Worth Buying Hand Over Fist

Alex CarchidiMar 2, 2023
crashing arrow

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

George Budwell, PhDFeb 10, 2023
scientist looks into microscope while sitting at lab bench

This Innovative Growth Stock Could Double or More in 2023

Alex CarchidiDec 22, 2022
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bionano Genomics

Bionano helps scientists and doctors analyze DNA for genetic changes. Its tools find hidden genetic differences that standard tests may miss. Hospitals and research labs use these solutions to better understand rare diseases and cancer.

Products and Services

  • OGM Systems: Instruments like Saphyr and Stratys scan DNA for large genetic changes; used by labs and hospitals.
  • Consumables (49% of revenue): Chips and kits needed for each DNA test; sold to research and clinical labs.
  • Software (22% of revenue): VIA and NxClinical platforms help analyze and interpret genetic data from multiple sources.
  • Testing and Other Services (6% of revenue): Includes laboratory tests (phased out in 2024-2025), hardware support, software hosting, and maintenance contracts.
  • Support and Maintenance: Hardware repairs, software hosting, and extended warranties for customers worldwide.

Growth and Expansion

  • Acquired Lineagen (2020), BioDiscovery (2021), and Purigen (2022) to add clinical testing, software, and DNA extraction technology.
  • Expanded product line with Stratys OGM system and VIA software upgrades in 2024-2025.
  • Entered new markets in Asia-Pacific and Europe, expanding international distribution.
  • Shifted focus in late 2024 to increasing use of existing systems instead of new placements.
  • Secured new U.S. reimbursement codes for OGM in 2025, supporting clinical adoption.

What Makes Bionano Stand Out

Bionano’s technology detects genetic changes that other methods may miss, using physical mapping instead of only sequencing. Its integrated workflow combines hardware, consumables, and software for a complete solution. The company’s global sales network reaches labs and hospitals in North America, Europe, and Asia-Pacific.

Five Things You Need to Know

  • Revenue was $28.5 million in 2025, down 7% from 2024.
  • Product gross margin rose to 46% in 2025, up from -5% in 2024.
  • Net loss improved to $26.4 million in 2025, from $112 million in 2024.
  • Installed base reached 387 OGM systems by December 31, 2025, up 4.3% year-on-year.
  • Cash and short-term investments totaled $19.3 million at year-end 2025.

Bottom Line

Bionano has evolved through acquisitions, product upgrades, and global expansion. The company focuses on advanced genome analysis but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

97

CEO

Robert Erik Holmlin, PhD, MBA

Website

www.bionano.com

Headquarters

San Diego, CA 92121, US

BNGO Financials

Key Financial Metrics (TTM)

Gross Margin

46.97%

Operating Margin

-114.03%

Net Income Margin

-109.95%

Return on Equity

-71.38%

Return on Capital

-64.94%

Return on Assets

-48.76%

Earnings Yield

-4.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.47M

Volume

69.45K

Avg. Volume

143.83K

Financials (TTM)

Gross Profit

$13.50M

Operating Income

-$32.77M

EBITDA

-$21.74M

Operating Cash Flow

-$19.30M

Capital Expenditure

$0.00

Free Cash Flow

-$19.30M

Cash & ST Invst.

$24.67M

Total Debt

$17.01M

Bionano Genomics Performance Analysis

Bionano Genomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 27,802,00054.6%
20232023-12-31USD 36,116,00029.9%
20242024-12-31USD 30,776,000-14.8%
20252025-12-31USD 28,508,000-7.4%
Bionano Genomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.3%
Q32025-09-309.4%
Q42025-12-317.9%
Q12026-03-31-15.9%
Bionano Genomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -275.0975.2%
20232023-12-31USD -408.4848.5%
20242024-12-31USD -88.13-78.4%
20252025-12-31USD -4.85-94.5%
Bionano Genomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-73.0%
Q32025-09-3020.1%
Q42025-12-318.2%
Q12026-03-3147.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.69M

+3.6%

Gross Profit

$3.25M

+10.7%

Gross Margin

48.63%

N/A

Market Cap

$12.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$131.14K

N/A

Employees

98

N/A

Net Income

-$8.30M

-167.7%

EBITDA

-$5.86M

-1016.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$24.67M

+35.3%

Total Debt

$17.01M

-7.6%

Accounts Receivable

$4.13M

+23.2%

Inventory

$5.31M

-44.5%

Long Term Debt

$5.97M

+69.3%

Short Term Debt

$11.04M

-25.8%

Return on Assets

-48.76%

N/A

Return on Invested Capital

-75.20%

N/A

Free Cash Flow

-$5.72M

-106.8%

Operating Cash Flow

-$5.72M

-106.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MYNZMainz Biomed B.V.
$3.59+0.84%
VYNEVYNE Therapeutics Inc.
$0.90+0.55%
QNRXQuoin Pharmaceuticals, Ltd.
$4.38+2.70%
XTLBXTL Biopharmaceuticals Ltd.
$2.92+5.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%
NOKNokia
$10.28-0.03%

Questions About BNGO

What is the current price of Bionano Genomics?

Bionano Genomics is trading at $1.12 per share.

What is the 52-week range for Bionano Genomics?

Over the past 52 weeks, Bionano Genomics has traded between $1.06 and $5.50.

How much debt does Bionano Genomics have?

As of the most recent reporting period, Bionano Genomics reported total debt of $17.01M.

How much cash does Bionano Genomics have on hand?

Bionano Genomics reported $13.69M in cash and cash equivalents in its most recent financial results.

What is Bionano Genomics’s dividend yield?

Bionano Genomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services